BCLI Research and Charts

BCLI - Brainstorm Cell Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 1.12	Change ⇑ +0.06 (+5.66%)	Volume 225,438
	Open 1.06	High 1.15	Low 1.05

8EMA (Daily) 1.14	40EMA (Daily) 1.17	50EMA (Daily) 1.19	STO (Daily) 30.140	MACD Hist (Daily) -0.023
8EMA (Weekly) 1.143	40EMA (Weekly) 1.25	50EMA (Weekly) 1.24	STO (Weekly) 35.333	MACD Hist (Weekly) -0.025


Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.